Legend Biotech (LEGN) director Gareth Kung reports 31,486 RSUs in Form 3

Rhea-AI Filing Summary

Legend Biotech Corp director Gareth Kung filed an initial ownership report showing 31,486 restricted share units (RSUs). Each RSU represents a contingent right to receive one ordinary share. Twenty-five percent of the RSUs vest on February 2, 2027, with the remainder vesting in eight equal quarterly installments beginning March 20, 2027, subject to continued service. The company’s ordinary shares may also be represented by American Depositary Shares, with each ADS equal to two ordinary shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kung Gareth

Role Director

Type	Security	Shares	Price	Value
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Ordinary Shares — 31,486 shares (Direct)

Footnotes (1)

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer. Includes 31,486 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 25% of the RSUs will vest on February 2, 2027 with the remainder vesting in 8 equal quarterly installments thereafter beginning on March 20, 2027, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kung Gareth

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

2101 COTTONTAIL LANE

(Street)

SOMERSET NEW JERSEY 08873

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	31,486(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Includes 31,486 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 25% of the RSUs will vest on February 2, 2027 with the remainder vesting in 8 equal quarterly installments thereafter beginning on March 20, 2027, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Pepin, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Legend Biotech (LEGN) director Gareth Kung report on this Form 3?

Gareth Kung reports initial ownership of 31,486 restricted share units (RSUs). Each RSU represents a contingent right to receive one ordinary share of Legend Biotech upon settlement, establishing his baseline equity-linked position as a director.

How do Gareth Kung’s RSUs at Legend Biotech (LEGN) vest over time?

25% of the 31,486 RSUs vest on February 2, 2027. The remaining RSUs vest in eight equal quarterly installments starting March 20, 2027, and require Gareth Kung’s continued service to Legend Biotech on each vesting date.

Are there any buy or sell transactions in this Legend Biotech (LEGN) Form 3?

No buy or sell transactions are reported in this Form 3. It serves as an initial statement of beneficial ownership, listing 31,486 RSUs as Gareth Kung’s reported equity-linked holdings rather than recording a new market trade.

How are Legend Biotech (LEGN) ordinary shares related to American Depositary Shares (ADSs)?

Each Legend Biotech ADS represents two ordinary shares. The filing notes that the company’s ordinary shares may be represented by ADSs, which trade in U.S. markets and bundle two underlying ordinary shares into each ADS unit.

What type of security does Gareth Kung hold in Legend Biotech (LEGN) according to this filing?

The filing reports 31,486 restricted share units (RSUs) in Legend Biotech. These RSUs are equity awards that convert into ordinary shares upon vesting and settlement, aligning the director’s compensation with the company’s long-term performance.